股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 華檢醫療控股有限公司 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01931 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 3,000,000,000 | USD | | 0.0005 | USD | | 1,500,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 3,000,000,000 | USD | | 0.0005 | USD | | 1,500,000 | 本月底法定/註冊 ...

Group 1 - A total of 78 stocks reached a 52-week high as of February 3, with notable performers including Asia Pacific Financial Investments (08193) at 57.14%, Chao Wei Holdings (08059) at 36.00%, and Asia Backup (08290) at 33.33% [1] - The closing prices for the top three stocks that reached new highs were 0.550, 0.052, and 0.024 respectively, with their highest prices being 0.550, 0.068, and 0.036 [1] - Other significant stocks that reached new highs include Huameilele (08429) with a high rate of 20.37% and Haode Holdings (08149) at 17.65% [1] Group 2 - The report also lists stocks that reached 52-week lows, with the worst performer being Gaodi Holdings (01676) at -10.00%, followed by Huajian Medical (01931) at -9.29% and Electronic Trading Group (08036) at -9.09% [3] - The closing prices for the stocks that reached new lows include 0.340, 1.280, and 0.021 respectively, with their lowest prices being 0.315, 1.270, and 0.020 [3] - Other notable stocks that reached new lows include Controllon (01912) at -8.93% and Cool Link (08491) at -8.11% [3]

Core Viewpoint - Huajian Medical's stock price increased by 16.88% following the announcement of a new detection solution for Nipah virus, indicating positive market response to the company's advancements in medical technology [1][3]. Group 1: Company Developments - On January 27, Huajian Medical announced that its subsidiary, Shenzhen Carbonhua Biotechnology Co., Ltd., successfully developed a dual-platform detection solution for Nipah virus, capable of comprehensive technical support from rapid screening to precise tracing [3]. - The intelligent fluorescence PCR rapid detection platform utilizes machine learning algorithms and a self-constructed species-specific nucleic acid database to efficiently identify and lock onto conserved gene regions of high-risk pathogens like Nipah virus, enabling rapid and accurate primer design and system optimization [3]. - The high-throughput sequencing and intelligent analysis platform relies on a continuously updated multi-species pathogen genome database, covering 18,628 types of pathogens, allowing for simultaneous detection and differentiation of Nipah virus and other coexisting pathogens [3]. - Huajian Medical emphasized that the rapid implementation of Nipah virus detection capabilities reflects the technological strength of Carbonhua Biotechnology and is a significant part of the company's overall AI medical strategy [3]. - The company is accelerating the construction of a next-generation public health prevention and control paradigm, integrating "AI early warning + rapid diagnosis + ecological collaboration," as it progresses with the acquisition of Chuangye Huikang [3].

Core Viewpoint - Huajian Medical (01931) has seen a stock increase of over 11%, currently at 1.78 HKD, with a trading volume of 20.59 million HKD, following the announcement of a dual-platform testing solution for Nipah virus developed by its subsidiary, Shenzhen Carbon Hua Biotechnology Co., Ltd [1] Group 1 - The dual-platform testing solution includes a smart fluorescence PCR rapid detection platform and a high-throughput sequencing and intelligent analysis platform, providing comprehensive technical support from rapid screening to precise tracing [1] - The rapid implementation of Nipah virus testing capabilities showcases the technological strength of Carbon Hua Biotechnology and represents a significant step in Huajian Medical's overall AI healthcare strategy [1] - The company is accelerating the establishment of a next-generation public health prevention and control paradigm, integrating "AI early warning + rapid diagnosis + ecological collaboration," as it progresses with the acquisition of Chuangye Huikang Technology Co., Ltd (300451.SZ) [1]

Core Viewpoint - Huajian Medical (01931) has seen a stock increase of over 11%, currently at 1.78 HKD, with a trading volume of 20.59 million HKD, following the announcement of a dual-platform testing solution for Nipah virus developed by its subsidiary, Shenzhen Carbonhua Biotechnology Co., Ltd [1] Group 1 - The dual-platform testing solution includes a smart fluorescence PCR rapid detection platform and a high-throughput sequencing and intelligent analysis platform, providing comprehensive technical support from rapid screening to precise tracing [1] - The successful development of the Nipah virus testing capability reflects the technological strength of Carbonhua Biotechnology and is a significant part of Huajian Medical's overall AI medical strategy [1] - The company is accelerating the construction of a next-generation public health prevention and control paradigm, integrating "AI early warning + rapid diagnosis + ecological collaboration," as it progresses with the acquisition of Chuangye Huikang Technology Co., Ltd (stock code: 300451.SZ) [1]

Core Viewpoint - The outbreak of Nipah virus in West Bengal, India, highlights the urgent need for rapid and accurate diagnostic and warning capabilities in global public health systems, with the World Health Organization classifying it as a deadly zoonotic virus with a mortality rate of 40% to 75% and no specific treatment or vaccine available [1] Group 1: Company Overview - Huajian Medical Holdings Limited is a high-tech intellectual property capital operation platform focused on the life sciences sector, closely monitoring global public health dynamics and providing technical support for the prevention and control of emerging infectious diseases [1] - The company’s subsidiary, Shenzhen Carbonhua Biotechnology Co., Ltd., is a high-tech enterprise established through a strategic investment with Carbon Cloud Intelligence, focusing on molecular diagnostics and offering comprehensive solutions in research, production, and technical services [1] Group 2: Technological Solutions - Carbonhua Biotechnology has developed a dual-platform detection solution for Nipah virus, capable of supporting the entire process from rapid screening to precise tracing [1] - The intelligent fluorescent PCR rapid detection platform utilizes an AI primer design platform, integrating gene retrieval, automated primer design, and multi-dimensional performance evaluation, achieving rapid and accurate detection of high-risk pathogens like Nipah virus [2] - The high-throughput sequencing and intelligent analysis platform offers a localized sequencing solution covering both "wet experiments and dry analysis," enabling simultaneous detection and differentiation of Nipah virus and other co-existing pathogens [4] Group 3: Strategic Development - The rapid deployment of Nipah virus detection capabilities reflects the technological strength of Carbonhua Biotechnology and is a significant step in Huajian Medical's overall AI healthcare strategy [6] - The company is advancing its acquisition of Chuangye Huikang Technology Co., Ltd., aiming to establish a next-generation public health prevention paradigm that integrates AI early warning, rapid diagnosis, and ecological collaboration [6] - The product launch and strategic articulation demonstrate the company's commitment to the core paradigm of "intelligent capital driving continuous profit from knowledge," enhancing innovation efficiency and commercial value within its ecosystem through technology integration, data collaboration, and capital empowerment [6]

Core Viewpoint - The outbreak of Nipah virus in West Bengal, India, highlights the urgent need for rapid and accurate diagnostic and warning capabilities in global public health systems, with a mortality rate of 40% to 75% and no specific treatment or vaccine available [1] Group 1: Company Overview - Huajian Medical is a high-tech intellectual property capital operation platform focused on the life sciences sector, closely monitoring global public health dynamics and providing technical support for the prevention and control of emerging infectious diseases [1] - The company’s subsidiary, Shenzhen Carbonhua Biotechnology Co., Ltd., specializes in molecular diagnostics and aims to provide comprehensive solutions in this field through research, production, and technical services [1] Group 2: Technological Advancements - Carbonhua Biotechnology has developed a dual-platform detection solution for Nipah virus, which includes a rapid screening and precise tracing capability [2] - The intelligent fluorescence PCR rapid detection platform utilizes an AI primer design platform to efficiently identify and lock onto conserved gene regions of high-risk pathogens, ensuring high specificity and sensitivity in detection [2] - The high-throughput sequencing and intelligent analysis platform offers a localized sequencing solution that can detect and differentiate Nipah virus and other coexisting pathogens, completing the process from sample receipt to report generation within 17 hours [3] Group 3: Strategic Implications - The rapid response to Nipah virus detection demonstrates the integrated technological capabilities of Huajian Medical in public health emergencies and is a significant validation of its strategic direction [4] - The company aims to establish a replicable intelligent public health monitoring system adaptable to various emerging infectious diseases and chronic disease management scenarios [4] - The product launch and strategic outline reflect the company's commitment to the core paradigm of "intelligent capital driving continuous knowledge profitability" and enhancing the innovative efficiency and commercial value of enterprises within its ecosystem [4]

Core Viewpoint - The outbreak of Nipah virus in West Bengal, India, highlights the urgent need for rapid and accurate diagnostic and warning capabilities in global public health systems, with the infection fatality rate reaching 40% to 75% and no specific treatment or vaccine available [1] Group 1: Company Overview - Huajian Medical is a high-tech intellectual property capital operation platform focused on the life sciences sector, closely monitoring global public health dynamics and providing technical support for infectious disease prevention and control [1] - The company’s subsidiary, Shenzhen Carbon Hua Biotechnology Co., Ltd., specializes in molecular diagnostics and aims to provide comprehensive solutions in this field [1] Group 2: Technological Advancements - Carbon Hua has developed a dual-platform detection solution for Nipah virus, which includes a rapid screening platform and a high-throughput sequencing and intelligent analysis platform [2] - The intelligent fluorescence PCR rapid detection platform utilizes an AI primer design platform to efficiently identify and lock onto conserved gene regions of high-risk pathogens, ensuring high specificity and sensitivity in detection [2] - The high-throughput sequencing and intelligent analysis platform offers a localized sequencing solution that can detect and differentiate Nipah virus and other co-existing pathogens, completing the process from sample receipt to report generation within 17 hours [3] Group 3: Strategic Implications - The rapid response to Nipah virus detection demonstrates the integrated technical capabilities of Huajian Medical in public health emergencies and marks a significant step in advancing the company's AI medical strategy [3] - The company aims to establish a replicable intelligent public health monitoring system adaptable to various emerging infectious diseases and chronic disease management scenarios [4] - The product launch and strategic outline reflect the company's commitment to the core paradigm of "intelligent capital driving continuous knowledge profitability" [4]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 華檢醫療控股有限公司 ETHK Labs Inc. （於開曼群島註冊成立之有限公司） （前稱 IVD Medical Holding Limited ） （股份代號：1931） 自願性公告 關於子公司成功研發尼帕病毒檢測雙平台解決方案及 集 團AI醫療戰略升級的進展 一、背景與契機 近 日，印 度 西 孟 加 拉 邦 暴 發 尼 帕 病 毒 疫 情，世 界 衛 生 組 織 已 將 其 列 為 致 命 性 人 畜 共 患 病 毒，感 染 死 亡 率 可 達40%至75%，且 目 前 尚 無 特 效 療 法 或 疫 苗。此 類 新 發 突 發 傳 染 病 疫 情 凸 顯 全 球 公 共 衛 生 體 系 對 快 速、精 準 診 斷 與 預 警 能 力 的 迫 切 需 求。 作 為 長 期 深 耕 生 命 科 學 領 域 的 高 科 技 知 識 產 權 資 ...

华检医疗(01931)公布，公司的英文名称已由"IVD Medical Holding Limited"更改为"ETHK Labs Inc."，而 公司的中文双语名称则维持不变，仍为"华检医疗控股有限公司"。公司的英文股份简称将由"IVD MEDICAL"更改为"ETHK LABS INC."，而公司于联交所买卖股份的中文股份简称则维持不变，仍 为"华检医疗"，自2026年1月30日上午九时正起生效。公司于联交所的股份代号将保持不变，仍 为"1931"。 ...